This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Related Collections
Right arrow Premature & Newborn
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

PEDIATRICS Vol. 103 No. 3 March 1999, pp. 684-685

AMERICAN ACADEMY OF PEDIATRICS:
Surfactant Replacement Therapy for Respiratory Distress Syndrome

Committee on Fetus and Newborn

Respiratory failure secondary to surfactant deficiency is a major cause of morbidity and mortality in low birth weight immature infants. Surfactant therapy substantially reduces mortality and respiratory morbidity for this population. The statement summarizes the indications for surfactant replacement therapy. Because respiratory insufficiency may be a component of multiorgan dysfunction in sick infants, surfactant should be administered only at institutions with qualified personnel and facilities for the comprehensive care of sick infants.

.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

The following policy statement is a revision:

Surfactant-Replacement Therapy for Respiratory Distress in the Preterm and Term Neonate
and
Pediatrics 121: 419-432. [Full Text]



This article has been cited by other articles:


Home page
 PediatricsHome page
W. A. Engle and and the Committee on Fetus and Newborn
Surfactant-Replacement Therapy for Respiratory Distress in the Preterm and Term Neonate
Pediatrics, February 1, 2008; 121(2): 419 - 432.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child. Fetal Neonatal Ed.Home page
F Sandri, G Ancora, A Lanzoni, P Tagliabue, M Colnaghi, M L Ventura, M Rinaldi, I Mondello, P Gancia, G P Salvioli, et al.
Prophylactic nasal continuous positive airways pressure in newborns of 28-31 weeks gestation: multicentre randomised controlled clinical trial
Arch. Dis. Child. Fetal Neonatal Ed., September 1, 2004; 89(5): F394 - F398.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
J. D. Horbar, J. H. Carpenter, J. Buzas, R. F. Soll, G. Suresh, M. B. Bracken, L. C. Leviton, P. E. Plsek, J. C. Sinclair, and for the members of the Vermont Oxford Network
Timing of Initial Surfactant Treatment for Infants 23 to 29 Weeks' Gestation: Is Routine Practice Evidence Based?
Pediatrics, June 1, 2004; 113(6): 1593 - 1602.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
R. Bruni
Focus on proteins, surfaces, et al.
Am J Physiol Lung Cell Mol Physiol, November 1, 2002; 283(5): L894 - L896.
[Full Text] [PDF]